Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice

J Immunol. 2003 Apr 15;170(8):4273-80. doi: 10.4049/jimmunol.170.8.4273.

Abstract

The HER-2/neu (neu-N)-transgenic mice are a clinically relevant model of breast cancer. They are derived from the parental FVB/N mouse strain and are transgenic for the rat form of the proto-oncogene HER-2/neu (neu). In this study, we report the identification of a MHC class I peptide in the neu protein that is recognized by CD8(+) T cells derived from vaccinated FVB/N mice. This 10-mer was recognized by all tumor-specific FVB/N T cells generated regardless of the TCR Vbeta region expressed by the T cell or the method of vaccination used, establishing it as the immunodominant MHC class I epitope in neu. T cells specific for this epitope were able to cure FVB/N mice of transplanted neu-expressing tumor cells, demonstrating that this is a naturally processed peptide. Altered peptide analogs of the epitope were analyzed for immunogenicity. Vaccination with dendritic cells pulsed with a heteroclitic peptide provided FVB/N and neu-N mice with increased protection against tumor challenge as compared with mice immunized with dendritic cells loaded with either wild-type or irrelevant peptide. Discovery of this epitope allows for better characterization of the CD8(+) T cell responses in the neu-N mouse model in which neu-specific tolerance must be overcome to produce effective antitumor immunity.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3T3 Cells
  • Adoptive Transfer
  • Animals
  • Antigen Presentation* / genetics
  • Cell Line, Transformed
  • Clone Cells
  • Epitopes, T-Lymphocyte / administration & dosage
  • Epitopes, T-Lymphocyte / biosynthesis
  • Epitopes, T-Lymphocyte / genetics
  • Epitopes, T-Lymphocyte / immunology
  • Genes, erbB-2 / immunology*
  • Graft Rejection / genetics
  • Graft Rejection / immunology
  • Growth Inhibitors / administration & dosage
  • Growth Inhibitors / biosynthesis
  • Growth Inhibitors / genetics
  • Growth Inhibitors / immunology
  • H-2 Antigens / genetics
  • H-2 Antigens / immunology
  • H-2 Antigens / isolation & purification
  • H-2 Antigens / metabolism*
  • Histocompatibility Antigen H-2D
  • Humans
  • Immunodominant Epitopes / genetics
  • Immunodominant Epitopes / isolation & purification*
  • Immunodominant Epitopes / metabolism*
  • Injections, Intravenous
  • Mammary Neoplasms, Experimental / genetics
  • Mammary Neoplasms, Experimental / immunology*
  • Mammary Neoplasms, Experimental / pathology
  • Mammary Neoplasms, Experimental / prevention & control
  • Mice
  • Mice, Inbred Strains
  • Mice, Transgenic
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / biosynthesis
  • Peptide Fragments / genetics
  • Peptide Fragments / immunology
  • Peptide Mapping
  • Proto-Oncogene Mas
  • Rats
  • T-Lymphocyte Subsets / immunology
  • T-Lymphocyte Subsets / metabolism
  • T-Lymphocyte Subsets / transplantation
  • Vaccines, DNA / administration & dosage
  • Vaccines, DNA / genetics
  • Vaccines, DNA / immunology

Substances

  • Epitopes, T-Lymphocyte
  • Growth Inhibitors
  • H-2 Antigens
  • Histocompatibility Antigen H-2D
  • Immunodominant Epitopes
  • MAS1 protein, human
  • Peptide Fragments
  • Proto-Oncogene Mas
  • Vaccines, DNA